Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JR-141 Extension Study in Mucopolysaccharidosis Type II
NCT04348136Phase 3Active, not recruiting
- Sponsor
- JCR Pharmaceuticals
- Start
- Sep 2019
- Primary completion
- Mar 2030
- Modality
- Replacement Enzymes, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 3 trial of pabinafusp alfa in mucopolysaccharidosis type 2, sponsored by JCR Pharmaceuticals. Started Sep 2019; status: active, not recruiting.
02
Drugs
pabinafusp alfa
03
Conditions
mucopolysaccharidosis type 2
Beyond the preview
Go deeper on NCT04348136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04348136.